옵션 체인은 다양한 행사가격과 만기일에 대한 Liquidia의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Liquidia에 대한 시장 심리를 평가합니다..

Liquidia (NASDAQ:LQDA) 주식, 옵션 체인

Liquidia

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Liquidia Corp

Baird analyst Michael Ha maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Neutral and raises the price target from $270 to $300.

News

Price Target

Analyst Ratings

Baird Maintains Neutral on Humana, Raises Price Target to $300

Targets Sustainable AI and Bitcoin Growth
Soluna Holdings, Inc. ("Soluna" or the "Company"), (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNH#NASDAQ">SLNH</a>), a developer of green data centers for intensive computing applications including Bitcoin mining and AI, announced today that it has signed the necessary definitive agreements to secure two parcels of land required to build Project Kati in Texas.
Project Kati is a 166 MW data center site that will power advanced computing applications, including Bitcoin mining and, potentially, artificial intelligence (AI). The project is in partnership with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.edf-re.com%2Fpress-release%2Fedf-renewables-north-america-and-masdar-sign-power-purchase-agreement-with-soluna-holdings%2F&amp;esheet=54238177&amp;newsitemid=20250415193813&amp;lan=en-US&amp;anchor=EDF+Renewables+and+Masdar&amp;index=1&amp;md5=a1ea4cac78836e62c80aa30242186411">EDF Renewables and Masdar</a>.
With two strategic land parcels now under contract—one for Bitcoin and one for AI—Soluna has cleared a major milestone in the development of the site. The shovel-ready project will be delivered in two phases, starting with 83 MW, and is expected to unlock new Bitcoin hosting and joint venture opportunities across the high-performance computing (HPC) landscape.

SLNH

Soluna Holdings Signs Definitive Agreements To Secure Two Parcels Of Land Required For 166 MW Project Kati In Texas

Asset Sales

Bunge To Sell North America Corn Milling Business, Terms Not Disclosed

<ul>
<li>Bell is the first operator globally to successfully field test AI-native link adaptation, a feature of&nbsp;Ericsson's 5G Advanced portfolio</li>
<li>This next-generation feature is being developed at&nbsp;Ericsson's Ottawa R&amp;D site&nbsp;&nbsp;</li>
</ul>
OTTAWA, ON and MONTRÉAL, April 15, 2025 /CNW/ -- Bell Canada and Ericsson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIC#NASDAQ">ERIC</a>) have conducted a successful field test of AI-native link adaptation – the first globally. This innovative technology uses real-time AI to dynamically adapt networks in response to changes in signal quality, interference, and other factors. The result is an enhanced user experience through increased throughput and spectral efficiency. This collaboration marks a significant breakthrough in applying artificial intelligence to improve the performance of radio access networks (RAN).
AI-native link adaptation dynamically optimizes spectral efficiency across mobile networks, significantly improving network performance. The in-field tests with Bell demonstrated:
<ul>
<li>Improved network user experience: Up to 20 percent higher downlink throughput, facilitating benefits such as faster download speeds.</li>
<li>More efficient use of network capacity: Increased spectral efficiency by up to 10 percent, improving capacity and reliability of connections.</li>
</ul>

ERIC

Ericsson And Bell Canada Successfully Test AI-Native Link Adaptation To Boost Network Speed And Efficiency

Baird analyst Michael Ha maintains CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with a Neutral and raises the price target from $51 to $71.

Baird Maintains Neutral on CVS Health, Raises Price Target to $71

Citigroup analyst Jason Bazinet reinstates Omnicom Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMC#NYSE">OMC</a>) with a Buy and announces $103 price target.

Initiation

Citigroup Reinstates Buy on Omnicom Group, Announces $103 Price Target

CBLL

CeriBell Granted FDA 510(k) Clearance For Its Clarity Algorithm In The Detectoin Of Electrographic Seizures For Patients Ages 1 Year And Older

New Partnership Debuts America-First Themed Investment Vehicles
SARASOTA, Fla., April 15, 2025 (GLOBE NEWSWIRE) -- Trump Media and Technology Group Corp. (Nasdaq, NYSE Texas: <a href="https://www.benzinga.com/stock/djt#Nasdaq,%20NYSE%20Texas">DJT</a>) ("TMTG" or "the Company"), operator of the social media platform Truth Social, the streaming platform Truth+, and the FinTech brand Truth.Fi, along with Yorkville America Equities, an America-First asset management firm, and Index Technologies Group (ITG), an originator and provider of thematic investment solutions, today announced that the three firms have created a strategic partnership and launched a new suite of Truth Social-branded Separately Managed Accounts ("SMAs"). These investment strategies offer investors access to curated, thematic investment strategies rooted in American values and priorities.
The initial lineup of SMA strategies includes:
<ul>
<li>Faith &amp; Values</li>
<li>Liberty &amp; Security</li>
<li>Energy Independence</li>
<li>Made in America</li>
</ul>

Trump Media Launches Separately Managed Accounts; Trump Media, Yorkville America Equities And Index Technologies Launch America-First Investment Partnership Featuring Truth Social-Branded SMAs Focused On Faith, Liberty, Energy Independence, And Made-In-America Themes

Baird analyst Michael Ha maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Neutral and lowers the price target from $71 to $69.

Baird Maintains Neutral on Centene, Lowers Price Target to $69

Guidance

RENT

Rent The Runway Projects Double-digit Growth YoY In Ending Active Subscribers In FY25; Projects Q1 Revenue Between $68M-$70M (Estimate: $76.50M)

New indications discovered by applying active machine learning and using samples from the company's vast biobank of live-cell tumors specimens
Builds upon Predictive's biomarker discovery platform to select targeted patient cohorts to significantly de-risk clinical trials
PITTSBURGH, April 15, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POAI#NASDAQ">POAI</a>), a leader in AI-driven drug discovery, announced today that it has made significant progress along the continuum of biomarker discovery, drug discovery and drug repurposing. These latest developments build upon Predictive's ongoing initiative to combine its in-house biomarker identification platform with its AI screening capabilities.
Identifying new indications using active machine learning and a biobank of patient derived dissociated tumor cells (DTCs) represents a novel and commercially sustainable approach to repurposing abandoned oncology drugs.
"This efficient screening approach on a small, curated cohort of abandoned drugs identified three compounds that warrant further exploration in tumor indications that have never been examined in this way," said Dr. Arlette Uihlein, SVP of Translational Medicine and Drug Discovery and Medical Director at Predictive Oncology. "The work that we have done successfully demonstrates our ability to utilize our active machine learning and biobank of tumor samples to capture patient response heterogeneity in less than 12 weeks."
The results of Predictive's novel approach to identifying clinically viable abandoned drugs are compelling.
Three drugs gave strong results for both ovarian and colon tumors. Specifically, Afuresertib, Alisertib and Entinosta demonstrated the highest proportion of hits within those two tumor types. Notably, Alisertib and Entinostat outperformed Oxaliplatin, a standard of care drug in the colon tumor type, while Alisertib also outperformed Ribociclib, a standard of care in breast cancer.
Afuresertib, is an Akt inhibitor that was previously studied in esophageal cancer, multiple myeloma, and more recently, attempted in combination with paclitaxel in platinum resistant ovarian cancer.
Alisertib, a selective Aurora A Inhibitor previously studied for use in both EGFR-mutated non-small cell lung cancer (NSCLC) and metastatic breast cancer, showed strong tumor drug response in ovarian and colon tumors based on both Predictive's wet lab testing and AI models. This drug is currently being evaluated in clinical trials for recurrent/metastatic breast cancer and lung cancer.
Entinostat, an HDAC1/3 inhibitor which was previously studied in solid tumor types, including breast and pancreatic, had a strong tumor drug response in the company's colon sample models. This drug is currently in clinical trials for use as a combination therapy in patients with NSCLC and for the purpose of biomarker development.
Of particular significance to Predictive Oncology, this drug class was previously shown to induce mitochondrial dysfunction in colorectal cancer, which is a possible target for further exploration combining the company's high content imaging (HCI) assay and its proprietary and internally derived HCI analysis pipeline.
"Applying this approach to other sets of publicly available abandoned drugs is a next logical step," said Raymond Vennare, CEO of Predictive Oncology. "But, more importantly, from the perspective of partnering opportunities with pharmaceutical companies to retain or repurpose their own abandoned drugs, our methodology would be advantageous in terms of efficiently transitioning their abandoned drugs back to clinical trial readiness."

Biotech

General

POAI

Predictive Oncology Announces It Has Made Progress Along The Continuum Of Biomarker Discovery, Drug Discovery And Drug Repurposing

MURA

Mural Oncology Announces Plans To Explore Strategic Alternatives; Will Discontinue All Clinical Development Of Nemvaleukin

Baird analyst Michael Ha maintains Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Outperform and lowers the price target from $388 to $362.

Baird Maintains Outperform on Cigna Group, Lowers Price Target to $362

Gauzy's Long-Established 20,000 SqFt Production Facility in Florida, Originally Designated to Support U.S. Aeronautics Customers, Already Serves All Company Divisions, Including Architecture, Automotive, SafetyTech and Aeronautics
Gauzy Continues to Grow Its Operations at All Four of Its Proprietary Production Sites in Tel Aviv (IL), Melbourne (FL) Lyon (FR) and Stuttgart (GER)to Ensure Continuous and Optimized Delivery of Its Products
TEL AVIV, Israel, April 15, 2025 (GLOBE NEWSWIRE) -- Gauzy Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAUZ#NASDAQ">GAUZ</a>), a global leader in light and vision control technologies, today issues a statement providing updates on new tariffs announced by the United States Government earlier this month.
&nbsp;
Gauzy Ltd. is headquartered in Tel-Aviv Israel, with a major production site serving all four of its business divisions. Israel is one of only 20 countries to have signed a Free Trade Agreement (FTA) with the United States and was the first country ever to do so in 1985.
As of today, the new 2025 tariff policy issued by the United States Government will have minimal to no impact on Gauzy's product portfolio. This is due to the use of US originated intermediates, components or raw materials, and the substantial transformation these undergo within the United States at both its Melbourne, Florida facility and through integration by U.S.-based customers and partners. To further support our customers, the company will issue them a detailed report outlining these points.

GAUZ

Gauzy Says As Of Today, The New 2025 Tariff Policy Issued By The U.S. Government Will Have Minimal To No Impact On Gauzy's Product Portfolio

Management

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

CURRENC Group Names Wan Lung Eng CFO, Effective April 16, 2025

<h3>Gainers</h3>
<ul>
<li>SUNation Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUNE#NASDAQ">SUNE</a>) stock moved upwards by 18.1% to $0.03 during Tuesday's pre-market session. </li>
<li>Resources Connection (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGP#NASDAQ">RGP</a>) shares moved upwards by 13.57% to $6.19. The market value of their outstanding shares is at $204.8 million. </li>
<li>Babcock &amp; Wilcox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BW#NYSE">BW</a>) stock rose 6.51% to $0.44. The company's market cap stands at $41.4 million. </li>
<li>Skycorp Solar Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PN#NASDAQ">PN</a>) shares moved upwards by 5.84% to $3.08. The company's market cap stands at $83.1 million. </li>
<li>Energy Vault Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRGV#NYSE">NRGV</a>) shares rose 5.51% to $0.71. The market value of their outstanding shares is at $109.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Toro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TORO#NASDAQ">TORO</a>) shares decreased by 26.3% to $1.74 during Tuesday's pre-market session. The market value of their outstanding shares is at $33.2 million. </li>
<li>Xos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOS#NASDAQ">XOS</a>) stock fell 19.17% to $2.7. The market value of their outstanding shares is at $21.6 million. </li>
<li>YY Group Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YYGH#NASDAQ">YYGH</a>) shares decreased by 14.98% to $1.05. The market value of their outstanding shares is at $40.1 million. </li>
<li>LATAM Airlines Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTM#NYSE">LTM</a>) shares declined by 8.2% to $27.01. The company's market cap stands at $8.1 billion. </li>
<li>Greenwave Tech Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWAV#NASDAQ">GWAV</a>) shares declined by 7.7% to $0.21. The company's market cap stands at $8.3 million. </li>
<li>Heramba Electric (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PITA#NASDAQ">PITA</a>) stock declined by 7.45% to $0.22. The market value of their outstanding shares is at $9.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

GWAV

NRGV

PITA

SUNE

TORO

YYGH

11 Industrials Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Amesite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMST#NASDAQ">AMST</a>) shares rose 20.5% to $2.7 during Tuesday's pre-market session. The company's market cap stands at $10.7 million. </li>
<li>Sally Beauty Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBH#NYSE">SBH</a>) shares moved upwards by 11.99% to $9.47. The market value of their outstanding shares is at $966.0 million. </li>
<li>Sonder Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOND#NASDAQ">SOND</a>) shares rose 11.63% to $3.07. The company's market cap stands at $33.8 million. </li>
<li>Twin Vee PowerCats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEE#NASDAQ">VEEE</a>) shares moved upwards by 8.99% to $3.03. The company's market cap stands at $4.5 million. </li>
<li>Zapp Electric Vehicles Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZAPP#NASDAQ">ZAPP</a>) stock rose 8.45% to $0.64. The market value of their outstanding shares is at $5.0 million. </li>
<li>Jiuzi Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZXN#NASDAQ">JZXN</a>) shares moved upwards by 7.63% to $5.5. The market value of their outstanding shares is at $60.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Culp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CULP#NYSE">CULP</a>) shares declined by 15.2% to $3.39 during Tuesday's pre-market session. The company's market cap stands at $42.5 million. </li>
<li>Mixed Martial Arts Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MMA#AMEX">MMA</a>) shares declined by 10.44% to $1.03. The company's market cap stands at $10.7 million. </li>
<li>Unifi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UFI#NYSE">UFI</a>) stock decreased by 9.55% to $4.36. The market value of their outstanding shares is at $80.0 million. </li>
<li>TCTM Kids IT Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSA#NASDAQ">VSA</a>) shares fell 8.71% to $0.43. The company's market cap stands at $4.3 million. </li>
<li>Four Seasons Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FEDU#NYSE">FEDU</a>) stock fell 7.97% to $5.89. The company's market cap stands at $12.4 million. </li>
<li>QVC Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QVCGA#NASDAQ">QVCGA</a>) stock declined by 7.52% to $0.15. The company's market cap stands at $60.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMST

CULP

FEDU

JZXN

QVCGA

SOND

VEEE

ZAPP

12 Consumer Discretionary Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Mural Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MURA#NASDAQ">MURA</a>) shares increased by 31.1% to $1.35 during Tuesday's pre-market session. The company's market cap stands at $23.2 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock rose 20.36% to $2.36. The company's market cap stands at $3.3 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares rose 17.36% to $0.58. The market value of their outstanding shares is at $16.2 million. </li>
<li>Fractyl Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GUTS#NASDAQ">GUTS</a>) stock rose 15.61% to $1.15. The company's market cap stands at $55.3 million. </li>
<li>MetaVia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTVA#NASDAQ">MTVA</a>) shares increased by 14.13% to $2.1. The company's market cap stands at $18.1 million. </li>
<li>Precision BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>) shares increased by 12.73% to $5.03. The company's market cap stands at $52.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Elutia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELUT#NASDAQ">ELUT</a>) shares fell 54.7% to $0.91 during Tuesday's pre-market session. The market value of their outstanding shares is at $37.1 million. </li>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) shares decreased by 29.92% to $0.75. The company's market cap stands at $7.0 million. </li>
<li>Spruce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) stock fell 23.35% to $0.24. The company's market cap stands at $9.9 million. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) stock fell 21.34% to $1.4. The market value of their outstanding shares is at $18.6 million. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) shares decreased by 21.03% to $0.16. The market value of their outstanding shares is at $4.8 million. </li>
<li>Sophia Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPH#NASDAQ">SOPH</a>) stock decreased by 20.42% to $2.3. The company's market cap stands at $152.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DTIL

ELUT

ENSC

GOVX

GUTS

MTVA

ONMD

SOPH

SPRB

Longevity Health Holdings, Inc. - Common Stock

XAGE

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Baird analyst Michael Ha maintains Alignment Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALHC#NASDAQ">ALHC</a>) with a Outperform and raises the price target from $17 to $22.

ALHC

Baird Maintains Outperform on Alignment Healthcare, Raises Price Target to $22

<h3>Gainers</h3>
<ul>
<li>ARB IOT Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBB#NASDAQ">ARBB</a>) stock increased by 31.9% to $0.86 during Tuesday's pre-market session. The market value of their outstanding shares is at $22.6 million. </li>
<li>Ostin Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>) shares rose 17.49% to $0.94. The market value of their outstanding shares is at $25.7 million. </li>
<li>CISO Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CISO#NASDAQ">CISO</a>) stock increased by 17.45% to $0.47. The market value of their outstanding shares is at $6.8 million. </li>
<li>Telefonaktiebolaget L M (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIC#NASDAQ">ERIC</a>) stock increased by 6.97% to $7.97. The market value of their outstanding shares is at $26.5 billion. The company's, Q1 earnings came out today. </li>
<li>Smith Micro Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMSI#NASDAQ">SMSI</a>) shares rose 6.83% to $0.86. The market value of their outstanding shares is at $15.2 million. </li>
<li>Key Tronic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTCC#NASDAQ">KTCC</a>) shares rose 6.52% to $2.45. The market value of their outstanding shares is at $26.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Research Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSSS#NASDAQ">RSSS</a>) stock decreased by 57.8% to $1.01 during Tuesday's pre-market session. The market value of their outstanding shares is at $32.9 million. </li>
<li>Abits Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABTS#NASDAQ">ABTS</a>) stock fell 35.72% to $1.35. The market value of their outstanding shares is at $3.1 million. </li>
<li>Taoping (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TAOP#NASDAQ">TAOP</a>) shares fell 15.26% to $0.2. The company's market cap stands at $2.6 million. </li>
<li>eGain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGAN#NASDAQ">EGAN</a>) shares fell 13.61% to $4.0. The company's market cap stands at $112.5 million. </li>
<li>Applied Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) shares decreased by 12.11% to $4.72. The company's market cap stands at $1.0 billion. The company's, Q3 earnings came out yesterday. </li>
<li>Q2 Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QTWO#NYSE">QTWO</a>) shares decreased by 10.25% to $67.71. The company's market cap stands at $4.1 billion. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABTS

APLD

ARBB

CISO

EGAN

KTCC

QTWO

RSSS

SMSI

TAOP

12 Information Technology Stocks Moving In Tuesday's Pre-Market Session

Earnings

Press Releases

Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Liquidia Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference

Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025

Financing

Contracts

Liquidia Corporation Strengthens Financial Position by Amending HealthCare Royalty Agreement to Incrementally Add Up to $100 Million

Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update

Health Care

Liquidia Announces Poster Presentations at the American Thoracic Society (ATS) 2025 International Conference

Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder

Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference

UPDATE – Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference

Comments

Liquidia

Liquidia (LQDA) 옵션

Liquidia (NASDAQ:LQDA) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌